Related Experiment Video
Updated: May 29, 2026

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
Published on: August 29, 2012
Immunohistochemistry of affected tissue may guide cGVHD treatment decisions
K M Williams1, L W Ostrow, D M Loeb
1Department of Pediatric Hematology-Oncology, Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. williaki@mail.nih.gov
Abstract:
Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20+ and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.
More Related Videos
Related Concept Videos
Immunocytochemistry and Immunohistochemistry
These...
Cytomegalovirus Disease
Tumor Immunotherapy

